![\"\"](\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/07\/20260725_Peking_Union_Medical_College_Hospital_Therapeutic_Indications-768x432.png\")
<\/p>\n<\/p>\n
Company<\/strong><\/p>\n Peking Union Medical College Hospital (Academic)<\/p>\n Event Type<\/strong><\/p>\n Peer-Reviewed Publication (Investigator-Led Phase 3 Trial)<\/p>\n Modality<\/strong><\/p>\n Hypomethylating Agent + HDAC Inhibitor + Chemotherapy (Azacitidine + Chidamide + CHOP)<\/p>\n Asset<\/strong><\/p>\n AC-CHOP (Azacitidine, Chidamide, CHOP)<\/p>\n Target<\/strong><\/p>\n DNA Methyltransferases \/ Class I and IIb Histone Deacetylases<\/p>\n Disease Area<\/strong><\/p>\n Previously Untreated Peripheral T-Cell Lymphoma<\/p>\n A peer-reviewed multicenter phase 3 study from China compared azacitidine plus chidamide and CHOP with CHOP alone in 128 previously untreated patients with peripheral T-cell lymphoma. The experimental regimen did not significantly improve overall response, complete response, or progression-free survival. Median overall survival was longer, 46.2 versus 24.1 months, but the investigators cautioned that imbalanced post-protocol therapy may explain part of the difference. The publication supports continued biomarker work around epigenetic PTCL biology, but it does not establish AC-CHOP as a new standard.<\/p>\n Nine Chinese centers enrolled 128 patients. Treatment was assigned according to participating center rather than by individual randomization: 84 received azacitidine plus chidamide and CHOP, and 44 received CHOP.<\/p>\n Overall response was 60.7% with AC-CHOP and 54.6% with CHOP; complete response was 47.6% and 36.4%, respectively. Neither difference was statistically significant.<\/p>\n Median progression-free survival was 10.2 versus 8.4 months with a P value of 0.093. Median overall survival was 46.2 versus 24.1 months with a P value of 0.023.<\/p>\n Hematologic toxicity and infection were the most common adverse events and overall safety was described as comparable. Genomic profiling associated DNMT3A mutations with lower response and IDH2 or TP53 mutations with inferior survival.<\/p>\n Peripheral T-cell lymphomas frequently carry lesions in DNA methylation, chromatin regulation, and T-cell differentiation, including TET2, DNMT3A, IDH2, and related pathways. This creates a credible rationale for combining a hypomethylating agent and an HDAC inhibitor with cytotoxic therapy.<\/p>\n Azacitidine inhibits DNA methyltransferases after incorporation into nucleic acids, while chidamide inhibits class I and selected class IIb histone deacetylases. Their combination is intended to reverse malignant epigenetic states and sensitize lymphoma cells to CHOP.<\/p>\n The trial did not meet the more direct disease-control tests: response and progression-free survival were numerically higher but not statistically significant. The overall-survival result is therefore discordant and should be considered hypothesis-generating.<\/p>\n Post-protocol treatment imbalance can materially alter survival in PTCL, where salvage therapy, transplantation, and access vary. Without a corresponding PFS benefit and with nonrandom center allocation, the observed survival difference cannot securely be attributed to the experimental regimen.<\/p>\n Assignment by center permits systematic differences in case mix, pathology, supportive care, assessment practice, and later therapy. Unequal sample sizes and a total enrollment of 128 further limit precision, subgroup inference, and adjustment for baseline imbalance.<\/p>\n The online article is an unedited early-access manuscript. Editorial correction may refine details, and the final version plus supplementary material should be checked before translating results into protocols or cross-trial comparisons.<\/p>\n The DNMT3A, IDH2, and TP53 associations are biologically plausible risk signals, but they do not yet identify patients who preferentially benefit from AC-CHOP. A prognostic association is not a predictive treatment-selection biomarker.<\/p>\n A next-generation study would stratify or randomize within molecular subtypes, prespecify treatment-interaction analyses, centrally review pathology and response, and control post-protocol therapy. Integrated serial molecular profiling could test whether epigenetic therapy clears specific clones or merely changes early response kinetics.<\/p>\n The study is useful because it provides phase 3 evidence from a Chinese PTCL population, an area with meaningful disease burden and historically limited randomized data. It also tests an oral HDAC inhibitor developed and used in China in a biologically coherent combination.<\/p>\n For drug developers, the result argues against broad unselected epigenetic intensification of CHOP and favors biomarker-enriched or subtype-specific programs. It also illustrates why survival signals from center-assigned studies require confirmation before regulatory or commercial extrapolation.<\/p>\n Peripheral T-cell lymphoma is a heterogeneous group of aggressive mature T-cell malignancies. CHOP remains a common frontline backbone outside selected CD30-positive disease, but relapse is frequent and durable cure rates remain inadequate.<\/p>\n The investigator-led study was coordinated by Peking Union Medical College Hospital with eight additional Chinese centers. Azacitidine is a hypomethylating agent, chidamide is an oral histone-deacetylase inhibitor, and CHOP combines cyclophosphamide, doxorubicin, vincristine, and prednisone.<\/p>\n The study is informative precisely because it is not a clean positive. It tests a strong biological rationale at phase 3 and shows that adding two epigenetic agents to CHOP did not translate into a statistically reliable response or PFS gain in an unselected population.<\/p>\n The longer overall survival should generate a confirmatory hypothesis, not a practice-changing claim. The most valuable output may be the molecular dataset and the design lesson for subtype-selected PTCL trials.<\/p>\n Signal strength:<\/strong> 3\/5 \u2014 Medium-High. Importance:<\/strong> Medium-High \u2014 this is new phase 3 evidence in a core hematologic malignancy and directly tests dual epigenetic therapy in frontline PTCL. Confidence:<\/strong> High for the reported response, PFS, OS, and safety results; medium for causal interpretation of the OS signal and for biomarker implications because assignment was center-based, post-protocol therapy was imbalanced, and subgroups were small.<\/p>\n","protected":false},"excerpt":{"rendered":" A peer-reviewed multicenter phase 3 study from China compared azacitidine plus chidamide and CHOP with CHOP alone in 128 previously untreated patients with peripheral T-cell lymphoma. The experimental regimen did not significantly improve overall…<\/p>\n","protected":false},"author":1,"featured_media":2176,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,4],"tags":[190,191],"class_list":["post-2163","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-technology-modalities","tag-peking-union-medical-college-hospital","tag-peripheral-t-cell-lymphoma"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2163","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2163"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2163\/revisions"}],"predecessor-version":[{"id":2187,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2163\/revisions\/2187"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2176"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2163"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2163"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2163"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Summary<\/h4>\n
Biological Rationale<\/h4>\n
Efficacy Interpretation<\/h4>\n
Design Limitations<\/h4>\n
Biomarker Implications<\/h4>\n
Strategic and Regional Context<\/h4>\n
Company and Product Background<\/h4>\n
Signal Extraction<\/h4>\n
\n
InSilens Take<\/h4>\n
Signal Assessment<\/h4>\n